Stryker Corp (SYK) Stock Price, Quote & News

Company Profile

Stryker Corporation operates as a medical technology company. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, clinical communication and artificial intelligence-assisted virtual care platform technology, minimally invasive products for the t...

Industry: Medical Devices

Sector: Healthcare

Phone: (269) 385-2600

Fax: (269) 385-1062

Website: www.stryker.com

Address:

1941 Stryker Way, Portage, United States

zoey1970 Aug. 25 at 9:19 AM

$SYM Some robotic enthusiasts may find this article of interest When Robots Learn the Meaning of a Hug Why does a hug calm us down? Why does a gentle hand on the shoulder ease anxiety? The answer lies in specialized nerve fibers beneath our skin that transform simple contact into complex emotions. Now, scientists are teaching robots this same language of touch. A team led by Li et al. has created an artificial synaptic device that echoes the same nerve fibers in our skin that turn touch into comfort. Their innovation could fundamentally change how robots perceive and respond to human contact, potentially enabling more empathetic interactions in healthcare and social robotics applications where emotional connection matters most. Read more here if interested https://neuromorphiccore.ai/when-robots-learn-the-meaning-of-a-hug/ $ABB $SYK $NVDA $TSLA

1 · Reply

StockAutoPro Aug. 24 at 5:57 PM

$SYK: Buy target $392.22 Sell target $413.93 Strong earnings report could boost healthcare equipment stock's growth potential.

0 · Reply

Marcusjoback Aug. 22 at 7:49 PM

This ain't nothing, just wait until $SYK and $MBOT announces a co-distribution sales and marketing deal after approval drops that pushes rapid adoption! $MBOT to $8+ on FDA approval $MBOT to $14+ on Stryker sales distribution deal $MBOT to $20+ on $50 million yr 1 sales Why else did they enter into a collaboration pact 3 yrs ago.....connect the dots✌️ https://www.marketwatch.com/story/microbots-stock-rockets-on-heavy-volume-after-collaboration-pact-with-stryker-on-robotic-procedural-kits-2021-12-27?mod=mw_quote_news

1 · Reply

ZacksResearch Aug. 22 at 2:30 PM

$SYK beats estimates with robust Q2 results, showcasing disciplined execution. 📊 Adjusted EPS at $3.13 exceeded expectations, and 11.1% sales growth was driven by volume growth and favorable pricing. However, competitive risks, macro pressures, and elevated valuation limit near-term upside. ⚖️ Full analysis on Stryker's outlook here 👉 https://www.zacks.com/stock/news/2741529/strykers-robotics-and-global-gains-offset-by-macro-concerns?cid=sm-stocktwits-2-2741529-body-9031&ADID=SYND_STOCKTWITS_TWEET_2_2741529_BODY_9031

0 · Reply

ZacksResearch Aug. 22 at 1:30 PM

$SYK’s growth engine is firing… but is it enough? Mako robotics and global demand fueled a strong Q2, yet inflation, FX, and competition are weighing on near-term upside. Full breakdown here 👉 https://www.zacks.com/stock/news/2741529/strykers-robotics-and-global-gains-offset-by-macro-concerns?cid=sm-stocktwits-2-2741529-teaser-9029&ADID=SYND_STOCKTWITS_TWEET_2_2741529_TEASER_9029

0 · Reply

AlgoInstinct Aug. 22 at 3:24 AM

$SYK Medical technology company with diverse portfolio and innovation pipeline benefiting from aging demographics

0 · Reply

Marcusjoback Aug. 20 at 10:54 PM

Institutional vs Retail ownership $ISRG 83% vs 17% $SYK 77% vs 23% $MBOT 16% vs 84% I expect we'll lose a lot people soon on this board that sell on the approval news, and that's ok but just know that's simply the normal evolution of weak retail hands converting to institutions as more hedge funds buy in once we're over $5 dollars like you see with Intuitive & Stryker. For the last 3 years, Microbot & Stryker have been working together to co-develop LIBERTY remote robotic procedural disposable kits, so I expect a co-distribution and sales deal to be announced after approval and with Stryker's massive presence and leverage I can see $MBOT reaching $50 million sales yr 1 for ~ $1 billion market cap based on a 20x p/s you see in peers or ~ $20 per share and that's just the start so enjoy the ride✌️

1 · Reply

Icemania Aug. 20 at 6:23 PM

$SYK they just bought Gard medical

0 · Reply

Marcusjoback Aug. 19 at 6:32 PM

Ask yourself, did massive $SYK medical tech company with $23 Billion in annual revenues enter into a collaboration pact 3 yrs ago with tiny old $MBOT to co-develop Liberty procedural kits because they.... 1. like them? 2. wanted to do them a favor? 3. wanted to tap into the Billion dollar robotic remote catheter market? Connect the dots ✌️ https://www.marketwatch.com/story/microbots-stock-rockets-on-heavy-volume-after-collaboration-pact-with-stryker-on-robotic-procedural-kits-2021-12-27?mod=mw_quote_news

0 · Reply

Marcusjoback Aug. 18 at 5:09 PM

$MBOT has been working with $SYK for the last 3 years to develop Liberty procedural kits and I’m expecting a huge distribution deal upon FDA approval so we can immediately tap into this Billion dollar market and Stryker's existing massive Sales channel so we will NOT BE BRINGING THIS TO MARKET ALONE and need I remind you that Stryker's annual sales are $23 Billion! ✌️

2 · Reply

Stryker Q2: Record Mako Installation And High Utilization

Aug 19, 2025, 1:50 PM EDT - 5 days ago

Stryker: Strong Multi-Faceted Growth Continuing To Support The Shares

Aug 15, 2025, 8:00 AM EDT - 10 days ago

Stryker to host investor day

Aug 14, 2025, 8:00 AM EDT - 11 days ago

Stryker to participate in the 2025 Wells Fargo Securities Healthcare Conference

Aug 7, 2025, 2:20 PM EDT - 17 days ago

Tim Scannell, Former Stryker President & COO, Named Chair of Longeviti Neuro Solutions Amid $10M Capital Infusion From Soleus Capital

Aug 7, 2025, 8:00 AM EDT - 18 days ago

Stryker declares an $0.84 per share quarterly dividend

Jul 31, 2025, 9:59 PM EDT - 24 days ago

Stryker Corporation (SYK) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 4:55 PM EDT - 24 days ago

Stryker raises annual profit forecast on steady demand for surgical devices

Jul 31, 2025, 4:05 PM EDT - 24 days ago

Stryker reports second quarter 2025 operating results

Jul 31, 2025, 9:52 AM EDT - 25 days ago

10 stocks favored to gain up to 30% in a sector that has missed this year's rally

BSX CAH DXCM EW ISRG LLY PODD

Jul 29, 2025, 9:07 AM EDT - 27 days ago

Inari Medical, now part of Stryker, launches the all-new InThrill® Thrombectomy System, designed to address arteriovenous access and small vessel thrombus cases

Jul 11, 2025, 5:07 AM EDT - 6 weeks ago

North America Cystoscopes Market Outlook Report 2025-2033 Featuring Key Companies - Olympus, KARL STORZ, Stryker, PENTAX Medical, Richard Wolf, Ambu, Laborie Medical Technologies

Jul 1, 2025, 8:00 AM EDT - 7 weeks ago

Stryker to announce financial results for its second quarter of fiscal year 2025

Jun 26, 2025, 1:01 PM EDT - 2 months ago

The Big 3: NXT, ANET, SYK

ANET NXT

Jun 25, 2025, 8:15 AM EDT - 2 months ago

Stryker receives FDA clearance for Incompass Total Ankle System

Jun 3, 2025, 11:09 AM EDT - 2 months ago

The 3 Most Overvalued Stocks Top Managers Are Selling in 2025

MA NFLX

May 19, 2025, 1:01 PM EDT - 3 months ago

Stryker receives FDA clearance for OptaBlate® BVN Basivertebral Nerve Ablation System

May 15, 2025, 8:05 AM EDT - 3 months ago

Baron Opportunity Fund Q1 2025 Top Contributors And Detractors

AMZN AVGO CSGP MSFT NVDA SPOT TSLA

May 13, 2025, 8:23 PM EDT - 3 months ago

Stryker Corporation (SYK) Bank of America Securities 2025 Global Healthcare Conference (Transcript)

May 9, 2025, 5:42 PM EDT - 3 months ago

Stryker: Mako Spine And Shoulder Launching Is On Track (Downgrade To Hold)

May 5, 2025, 2:20 PM EDT - 3 months ago

Final Trades: Rockwell Automation, Alerian MLP, Lockheed Martin and Stryker

LMT ROK AMLP

May 1, 2025, 8:28 PM EDT - 4 months ago

Stryker Corporation (SYK) Q1 2025 Earnings Call Transcript

May 1, 2025, 6:33 PM EDT - 4 months ago

Stryker beats quarterly estimates of string medical device demand

May 1, 2025, 4:05 PM EDT - 4 months ago

Stryker reports first quarter 2025 operating results

Apr 29, 2025, 8:00 AM EDT - 4 months ago

Stryker to participate in the Bank of America Securities 2025 Global Healthcare Conference

Apr 1, 2025, 4:26 PM EDT - 5 months ago

Viscogliosi Brothers Completes Acquisition of U.S. Spine Business from Stryker, Creating VB Spine, LLC

Apr 1, 2025, 4:05 PM EDT - 5 months ago

Stryker completes sale of U.S. spinal implants business

Mar 26, 2025, 10:15 AM EDT - 5 months ago

Stryker announces intention to nominate Manny Maceda to board of directors

Mar 25, 2025, 4:15 PM EDT - 5 months ago

Stryker announces Annual Meeting of Shareholders

Mar 18, 2025, 1:01 PM EDT - 5 months ago

The Big 3: MMM, PM, SYK

MMM PM

Mar 11, 2025, 8:03 AM EDT - 5 months ago

Stryker showcases next generation of Mako SmartRobotics™ at AAOS 2025 Annual Meeting

Mar 6, 2025, 1:36 PM EST - 6 months ago

Inari Medical, now part of Stryker, launches Artix™ Thrombectomy System, designed to address a broad spectrum of arterial thrombus cases

Mar 4, 2025, 8:07 AM EST - 6 months ago

Stryker launches Steri-Shield 8 personal protection system

Mar 3, 2025, 8:07 AM EST - 6 months ago

Stryker launches Sync Badge

Feb 28, 2025, 5:24 PM EST - 6 months ago

Stryker Corporation (SYK) Citi's 2025 Unplugged Medtech and Life Sciences Access Day (Transcript)

Feb 20, 2025, 12:14 PM EST - 6 months ago

The Big 3: FTNT, NXT, SYK

FTNT NXT

Feb 19, 2025, 8:30 AM EST - 6 months ago

Stryker completes acquisition of Inari Medical, Inc., providing entry into the high-growth peripheral vascular segment

Feb 13, 2025, 5:54 PM EST - 6 months ago

Kadant Set to Join S&P SmallCap 600

KAI

Feb 13, 2025, 8:00 AM EST - 6 months ago

Stryker to participate in Citi's 2025 Unplugged Medtech and Life Sciences Access Day

Feb 10, 2025, 4:05 PM EST - 6 months ago

Stryker announces Allan Golston will retire from Board of Directors

Jan 31, 2025, 4:34 PM EST - 7 months ago

Sales Growth, Strategic Acquisitions Drive Stryker Higher

Jan 29, 2025, 1:48 PM EST - 7 months ago

Stryker's Strategic Moves Impress Analysts, Spine Implant Sale and NARI Deal Set to Drive Future Growth

Jan 28, 2025, 9:34 PM EST - 7 months ago

Stryker Corporation (SYK) Q4 2024 Earnings Conference Call Transcript

Jan 28, 2025, 5:33 PM EST - 7 months ago

Stryker forecasts 2025 profit above estimates on robust demand for surgical devices

Jan 28, 2025, 4:45 PM EST - 7 months ago

Overlooked Stock: SYK

Jan 28, 2025, 4:05 PM EST - 7 months ago

Stryker reports 2024 operating results and 2025 outlook

Jan 28, 2025, 4:05 PM EST - 7 months ago

Stryker announces definitive agreement for the sale of its U.S. spinal implants business and plans to sell related international business

Jan 28, 2025, 4:05 PM EST - 7 months ago

Stryker announces the retirement of Glenn S. Boehnlein and the promotion of Preston Wells to Vice President, Chief Financial Officer

Jan 27, 2025, 12:49 PM EST - 7 months ago

Stryker: A Cool Name For An Awesome Company, But Is It A Buy Ahead Of Earnings?

Jan 17, 2025, 4:20 PM EST - 7 months ago

Stryker commences tender offer for all outstanding shares of common stock of Inari Medical, Inc.

zoey1970 Aug. 25 at 9:19 AM

1 · Reply

StockAutoPro Aug. 24 at 5:57 PM

$SYK: Buy target $392.22 Sell target $413.93 Strong earnings report could boost healthcare equipment stock's growth potential.

0 · Reply

Marcusjoback Aug. 22 at 7:49 PM

1 · Reply

ZacksResearch Aug. 22 at 2:30 PM

0 · Reply

ZacksResearch Aug. 22 at 1:30 PM

0 · Reply

AlgoInstinct Aug. 22 at 3:24 AM

$SYK Medical technology company with diverse portfolio and innovation pipeline benefiting from aging demographics

0 · Reply

Marcusjoback Aug. 20 at 10:54 PM

1 · Reply

Icemania Aug. 20 at 6:23 PM

$SYK they just bought Gard medical

0 · Reply

Marcusjoback Aug. 19 at 6:32 PM

0 · Reply

Marcusjoback Aug. 18 at 5:09 PM

2 · Reply

StockAutoPro Aug. 14 at 5:52 PM

$SYK: Buy target $374.0 Sell target $394.8 Strong growth potential observed in leading orthopedic devices manufacturer; consider for long-term investment.

0 · Reply

TechTraderGrok Aug. 12 at 8:18 PM

Sold $SYK at $376.4 (-1.3%). From Grok: "Exit the long SYK position to cash as the downtrend has strengthened with price sustaining below recent lows and breaking supports amid weakening momentum, despite the initial capitulation signal." https://www.techtrader.ai/grokwall/?post=14395&utm_source=dlvr.it&utm_medium=stocktwits

0 · Reply

TheContessa Aug. 9 at 6:36 PM

$SYK Interesting to note that ISRG has a beta of 1.60 and SYK has a beta of 0.91 Volatility due to…?

1 · Reply

TheContessa Aug. 9 at 6:30 PM

$SYK TBH I’m not used to owning stocks of solid growth companies with betas under 1.00. It is strangely peaceful. 📈

0 · Reply

Marcusjoback Aug. 8 at 7:39 PM

Both $MBOT & Stereotaxis are robotic systems designed for endovascular procedures, but they differ significantly in their approach and use. LIBERTY emphasizes a single-use, disposable and potentially more cost-effective approach to a broader range of endovascular procedures using a compact and remote system that eliminates exposure to radiation while Stereotaxis is used for more minimally invasive cardiac ablation procedures to treat arrhythmias (irregular heart rhythms) using robotically controlled magnets to guide catheters. I give LIBERTY a big advantage because it should be way more cost-effective and can be used in a more broader range of procedures and MOST IMPORTANTLY $MBOT has been working with $SYK for the last 3 years to develop procedural kits so we can immediately tap into Stryker's existing massive Sales channel upon FDA approval so we will NOT BE BRINGING THIS TO MARKET ALONE UNLIKE Stereotaxis and need I remind you that Stryker's annual sales are $23 Billion! ✌️

2 · Reply

PhatRam32 Aug. 7 at 4:58 PM

$ISRG may as well sell this and throw funds at $SYK

0 · Reply

StockAutoPro Aug. 6 at 5:25 PM

$SYK: Buy target $376.31 Sell target $397.23 Strong pipeline of innovative drugs indicates potential for sustained growth in the biopharmaceutical company.

0 · Reply

Marcusjoback Aug. 5 at 5:14 PM

For the last 3 years $MBOT & $SYK have been working together to develop LIBERTY remote robotic procedural disposable kits to be used in neurovascular procedures so upon FDA approval we can immediately tap into Stryker's existing massive Sales channel and distribution so we will not be bringing this to market alone and need I remind you that Stryker's annual sales are $23 billion! The only question for me is will Stryker eventually acquire them for more or less than $10 billion? I’m going with slightly under ✌️

3 · Reply

TechTraderGrok Aug. 4 at 9:16 PM

Bought $SYK at $381.52. From Grok: "SYK's volume capitulation today at $380.3 signals a potential bottom after a post-earnings dip, supported by strong Q2 results with 11% sales growth, EPS beat, and raised 2025 guidance, in an unclear trend but with price near support." https://www.techtrader.ai/grokwall/?post=14301&utm_source=dlvr.it&utm_medium=stocktwits

1 · Reply

JarvisFlow Aug. 4 at 1:18 PM

Truist Securities has updated their rating for Stryker ( $SYK ) to Hold with a price target of 415.

0 · Reply

fade_bot9000 Aug. 4 at 5:08 AM

$SYK Breaking out of a 3-month consolidation above $340 on strong volume. Measured move suggests $360-365 target if breakout holds. Support now at $335 with the 50-day MA rising.

0 · Reply

scientificway Aug. 2 at 7:39 PM

$SYK check MDXG out, huge guidance

0 · Reply

Market Cap	150.71B
Revenue (ttm)	22.60B
Net Income (ttm)	2.99B
EPS (ttm)	N/A
PE Ratio	29.95
Forward PE	28.50
Profit Margin	13.25%
Debt to Equity Ratio	0.78

Volume	896,000
Avg Vol	1,286,626
Day's Range	N/A - N/A
Shares Out	382.31M
Stochastic %K	94%
Beta	0.91
Analysts	Strong Sell
Price Target	$437.77